Clinical Trial Update: Safety of a Live Attenuated Human Parainfluenza Virus Type 2 (HPIV2) Vaccine for Adults, Children, and Infants [Phase 1]

View source ↗

Summary

This Phase 1 trial evaluates the safety of a live attenuated Human Parainfluenza Virus Type 2 vaccine in adults, children, and infants. The study is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Parainfluenza Virus Infection

Drugs mentioned

• HPIV2 live attenuated vaccine (Live attenuated human parainfluenza virus type 2 vaccine)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Human Parainfluenza Virus 2 | Phase 1 | Status: COMPLETED